Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Common examples showing promise for weight loss and diabetes control include Victoza (liraglutide) and Mounjaro (tirzepatide ... blood sugar steady, often without needing a prescription or ...

These medications began as diabetes treatments to lower blood glucose levels and have now been approved to help people without diabetes lose weight ... and Ozempic), and tirzepatide (Mounjaro ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...